The decision governance layer for pharma R&D.
Decivio helps pharma teams turn fragmented clinical, safety, regulatory, operational, competitive and economic signals into explicit, traceable and executable development decisions.
A layer above your existing systems. Not another one to replace them.
More data. More AI. More signals. Still slow decisions.
Pharma R&D does not suffer from a lack of information. It suffers from the difficulty of converting fragmented, uncertain and sometimes contradictory signals into timely decisions that can be defended, executed and reviewed.
Decisions fragmented across functions
Every function sees part of the truth, clinical, safety, regulatory, CMC, operations, portfolio. The program decision stays blurry across slides, meetings and partial evidence.
Competition moves faster than internal alignment
A faster or better-differentiated competitor can erode a program's upside in months, while the board is still aligning.
Go by default, weakly conditioned
Programs continue by inertia. "Go" decisions too often lack explicit conditions, capital caps, triggers and owners.
No discipline after the board
Once decided, follow-up is informal. Triggers are not tracked, re-reviews slip, and the same patterns repeat with no decision memory.
From fragmented signals to a governed decision.
Decivio creates a structured Decision Object for each critical R&D arbitration, then turns it into board-ready outputs and post-decision governance.
Make the invisible parts of a decision visible.
Decivio brings evidence, strategic tension and accountability into one shared decision environment. The underlying method is calibrated to the program, the tollgate and the organization.
Clarify
Give every function a shared view of the question, the evidence and what remains uncertain.
Arbitrate
Surface the trade-offs that matter before they become delays, politics or implicit assumptions.
Govern
Turn the board's direction into a decision that remains traceable, actionable and reviewable.
Built for the decisions that engage the most capital.
Phase II → Phase III readiness
Structure the most expensive progression decision, evidence, conditions, competition and capital in one object.
Endpoint strategy
Compare endpoint options across clinical relevance, statistical risk, regulatory acceptability and differentiation.
Recruitment rescue & re-scope
Link enrollment delays to cost, readout risk and re-scoping options, with clear triggers.
Competitive response
Recalculate upside when a competitor moves faster, then decide to accelerate, re-scope, pause or stop.
Safety re-review
Turn safety reserves into explicit conditions, thresholds and disciplined re-review.
Portfolio reprioritization
Make programs comparable, make capital at risk visible, and reallocate with a defensible rationale.
Signals are accelerating. Decisions are not.
Development costs keep rising, AI multiplies the volume and speed of R&D signals, and late continuation still burns capital. The organizations that win will be those that convert signals into governed decisions fastest.
What changes with a decision layer.
Decivio does not claim to eliminate scientific failure. It targets avoidable value leakage: delayed decisions, implicit continuation, unresolved contradictions, underweighted competition and weak post-decision follow-up.
Test Decivio on a real tollgate, in 10 to 12 weeks.
Apply Decivio to one upcoming tollgate and discover what changes when evidence, alignment and follow-through become one governed process.